{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:59:54Z","timestamp":1793177994244,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00262-021-02905-8","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T10:02:56Z","timestamp":1616752976000},"page":"3105-3111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area"],"prefix":"10.1007","volume":"70","author":[{"given":"Gregory R.","family":"Stroh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-1035","authenticated-orcid":false,"given":"Patricio","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"3","key":"2905_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153\u2013167","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2905_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27(4):195\u2013201","journal-title":"Trends Immunol"},{"issue":"24","key":"2905_CR3","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"issue":"21","key":"2905_CR4","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378(21):1976\u20131986","journal-title":"N Engl J Med"},{"issue":"6","key":"2905_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4161\/cbt.28555","volume":"15","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M et al (2014) Melanoma immunotherapy. Cancer Biol Ther 15(6):665\u2013674","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"2905_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290","journal-title":"N Engl J Med"},{"issue":"4","key":"2905_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574","journal-title":"Ann Oncol"},{"issue":"5","key":"2905_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14740338.2017.1313228","volume":"16","author":"C Genova","year":"2017","unstructured":"Genova C et al (2017) Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. Expert Opin Drug Saf 16(5):573\u2013585","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"2905_CR9","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo M et al (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63(11):1490\u20131493","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2905_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91\u2013104","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2905_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/eji.200535458","volume":"36","author":"SC Liang","year":"2006","unstructured":"Liang SC et al (2006) PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol 36(1):58\u201364","journal-title":"Eur J Immunol"},{"key":"2905_CR12","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.2147\/OTT.S178246","volume":"11","author":"W He","year":"2018","unstructured":"He W et al (2018) Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. Onco Targets Ther 11:7423\u20137427","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2905_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","volume":"7","author":"A Anastasopoulou","year":"2019","unstructured":"Anastasopoulou A et al (2019) Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer 7(1):239","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2905_CR14","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","volume":"12","author":"YC Chu","year":"2017","unstructured":"Chu YC et al (2017) Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma. J Thorac Oncol 12(8):e111\u2013e114","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2905_CR15","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","volume":"11","author":"K Fujita","year":"2016","unstructured":"Fujita K, Terashima T, Mio T (2016) Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 11(12):2238\u20132240","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2905_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","volume":"55","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Chan A, Tang T (2016) Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin\u2019s lymphoma. Acta Oncol 55(4):519\u2013520","journal-title":"Acta Oncol"},{"issue":"3","key":"2905_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","volume":"24","author":"H Picchi","year":"2018","unstructured":"Picchi H et al (2018) Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect 24(3):216\u2013218","journal-title":"Clin Microbiol Infect"},{"key":"2905_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","volume":"198","author":"PT Elkington","year":"2018","unstructured":"Elkington PT et al (2018) Implications of tuberculosis reactivation after immune checkpoint inhibition. Am J Respir Crit Care Med 198:1451\u20131453","journal-title":"Am J Respir Crit Care Med"},{"issue":"475","key":"2905_CR19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/scitranslmed.aat2702","volume":"11","author":"DL Barber","year":"2019","unstructured":"Barber DL et al (2019) Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med 11(475):2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"2905_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","volume":"57","author":"KH Jensen","year":"2018","unstructured":"Jensen KH et al (2018) Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. Acta Oncol 57(8):1127\u20131128","journal-title":"Acta Oncol"},{"issue":"1","key":"2905_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","volume":"25","author":"S Takata","year":"2019","unstructured":"Takata S et al (2019) Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J Infect Chemother 25(1):54\u201358","journal-title":"J Infect Chemother"},{"issue":"1","key":"2905_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/qjmed\/hcy243","volume":"112","author":"CC Tsai","year":"2019","unstructured":"Tsai CC et al (2019) Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment. QJM 112(1):41\u201342","journal-title":"QJM"},{"key":"2905_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fonc.2019.00659","volume":"9","author":"R van Eeden","year":"2019","unstructured":"van Eeden R et al (2019) Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review. Front Oncol 9:659","journal-title":"Front Oncol"},{"issue":"7","key":"2905_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CJI.0000000000000324","volume":"43","author":"JS Song","year":"2020","unstructured":"Song JS, Jeffery CC (2020) Laryngeal tuberculosis in a patient on avelumab for metastatic nasopharyngeal carcinoma. J Immunother 43(7):222\u2013223","journal-title":"J Immunother"},{"issue":"6","key":"2905_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2020-0061","volume":"12","author":"Y Kato","year":"2020","unstructured":"Kato Y et al (2020) Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report. Immunotherapy 12(6):373\u2013378","journal-title":"Immunotherapy"},{"issue":"4","key":"2905_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/17843286.2019.1629078","volume":"75","author":"V Inthasot","year":"2020","unstructured":"Inthasot V et al (2020) Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases. Acta Clin Belg 75(4):308\u2013310","journal-title":"Acta Clin Belg"},{"issue":"4","key":"2905_CR27","doi-asserted-by":"publisher","first-page":"e000866","DOI":"10.1136\/esmoopen-2020-000866","volume":"5","author":"K Anand","year":"2020","unstructured":"Anand K et al (2020) Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 5(4):e000866","journal-title":"ESMO Open"},{"key":"2905_CR28","doi-asserted-by":"publisher","first-page":"52668","DOI":"10.7554\/eLife.52668","volume":"9","author":"LB Tezera","year":"2020","unstructured":"Tezera LB et al (2020) Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha. Elife 9:52668","journal-title":"Elife"},{"key":"2905_CR29","first-page":"91","volume":"18","author":"KD Kauffman","year":"2020","unstructured":"Kauffman KD et al (2020) PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques. bioRxiv 18:91","journal-title":"bioRxiv"},{"issue":"12","key":"2905_CR30","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","volume":"11","author":"T Reungwetwattana","year":"2016","unstructured":"Reungwetwattana T, Adjei AA (2016) Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 11(12):2048\u20132050","journal-title":"J Thorac Oncol"},{"key":"2905_CR31","unstructured":"Health MDo. Tuberculosis, 2018. 2019. https:\/\/www.health.state.mn.us\/diseases\/reportable\/dcn\/sum18\/tb.html"},{"key":"2905_CR32","unstructured":"University M. The Online TST\/IGRA Interpretor Version 3.0. http:\/\/www.tstin3d.com\/en\/calc.html"},{"issue":"3","key":"2905_CR33","doi-asserted-by":"publisher","first-page":"e32482","DOI":"10.1371\/journal.pone.0032482","volume":"7","author":"M Santin","year":"2012","unstructured":"Santin M, Munoz L, Rigau D (2012) Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS ONE 7(3):e32482","journal-title":"PLoS ONE"},{"issue":"11","key":"2905_CR34","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ibd.22901","volume":"18","author":"N Shahidi","year":"2012","unstructured":"Shahidi N et al (2012) Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 18(11):2034\u20132042","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2905_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4049\/jimmunol.1200061","volume":"190","author":"AM Green","year":"2013","unstructured":"Green AM, Difazio R, Flynn JL (2013) IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol 190(1):270\u2013277","journal-title":"J Immunol"},{"key":"2905_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2334-4-44","volume":"4","author":"R Suarez-Mendez","year":"2004","unstructured":"Suarez-Mendez R et al (2004) Adjuvant interferon gamma in patients with drug\u2014resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 4:44","journal-title":"BMC Infect Dis"},{"issue":"9","key":"2905_CR37","doi-asserted-by":"publisher","first-page":"e6984","DOI":"10.1371\/journal.pone.0006984","volume":"4","author":"R Dawson","year":"2009","unstructured":"Dawson R et al (2009) Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS ONE 4(9):e6984","journal-title":"PLoS ONE"},{"issue":"8","key":"2905_CR38","doi-asserted-by":"publisher","first-page":"e43733","DOI":"10.1371\/journal.pone.0043733","volume":"7","author":"IY Nikitina","year":"2012","unstructured":"Nikitina IY et al (2012) Mtb-specific CD27low CD4 T cells as markers of lung tissue destruction during pulmonary tuberculosis in humans. PLoS ONE 7(8):e43733","journal-title":"PLoS ONE"},{"issue":"30","key":"2905_CR39","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1073\/pnas.1007394107","volume":"107","author":"E Lazar-Molnar","year":"2010","unstructured":"Lazar-Molnar E et al (2010) Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A 107(30):13402\u201313407","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2905_CR40","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","volume":"186","author":"DL Barber","year":"2011","unstructured":"Barber DL et al (2011) CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 186(3):1598\u20131607","journal-title":"J Immunol"},{"issue":"5","key":"2905_CR41","doi-asserted-by":"publisher","first-page":"e1005667","DOI":"10.1371\/journal.ppat.1005667","volume":"12","author":"S Sakai","year":"2016","unstructured":"Sakai S et al (2016) CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. PLoS Pathog 12(5):e1005667","journal-title":"PLoS Pathog"},{"issue":"5","key":"2905_CR42","doi-asserted-by":"publisher","first-page":"e19864","DOI":"10.1371\/journal.pone.0019864","volume":"6","author":"S Tousif","year":"2011","unstructured":"Tousif S et al (2011) T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS ONE 6(5):e19864","journal-title":"PLoS ONE"},{"issue":"1","key":"2905_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrmicro732","volume":"1","author":"A Casadevall","year":"2003","unstructured":"Casadevall A, Pirofski LA (2003) The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1(1):17\u201324","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"2905_CR44","doi-asserted-by":"publisher","first-page":"e1005739","DOI":"10.1371\/journal.ppat.1005739","volume":"12","author":"PL Lin","year":"2016","unstructured":"Lin PL et al (2016) PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis. PLoS Pathog 12(7):e1005739","journal-title":"PLoS Pathog"},{"key":"2905_CR45","doi-asserted-by":"publisher","first-page":"105853","DOI":"10.1016\/j.rmed.2019.105853","volume":"161","author":"Y Im","year":"2020","unstructured":"Im Y et al (2020) Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respir Med 161:105853","journal-title":"Respir Med"},{"issue":"5","key":"2905_CR46","doi-asserted-by":"publisher","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K et al (2020) Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors. Open Forum Infect Dis 7(5):ofaa126","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2905_CR47","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","volume":"21","author":"EA Langan","year":"2020","unstructured":"Langan EA et al (2020) Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol 21(1):e55\u2013e65","journal-title":"Lancet Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02905-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:33:55Z","timestamp":1671719635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02905-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02905-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GRS has no relevant financial or non-financial interests to disclose. TP participated in Advisory Boards for AstraZeneca and Novocure, outside the scope of the submitted work. All fees were paid to Mayo Clinic. PE participated in a short-term advisory scientific board for DiaSorin Molecular, which was outside the scope of the submitted work. Honorarium was paid to Mayo Clinic. PE has also filed two patent applications related to immunodiagnostic laboratory methodologies for latent tuberculosis infection for intellectual property protection purposes. To date, there has been no income or royalties associated with those filed patent applications. Otherwise, PE does not have other conflicts of interest COI to disclose. This paper\u2019s contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or Mayo Clinic. No other financial or material support for this work was provided to the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}